Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01417403 · ClinicalTrials.gov registry record · Phase 1
Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01417403 is a Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 10 participants.
The verdict
NCT01417403, a Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of hydroxychloroquine in treating patients with solid tumors undergoing radiation therapy for bone metastases. Drugs, such as hydroxychloroquine, may make tumor cells more sensitive to radiation therapy
Interventions
- RADIATION radiation therapy
- DRUG hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01417403
The ClinicalTrials.gov registry entry for NCT01417403 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT01417403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01417403 about?
NCT01417403 is a clinical study titled "Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases". This phase I trial studies the side effects and best dose of hydroxychloroquine in treating patients with solid tumors undergoing radiation therapy for bone metastases. Drugs, such as hydroxychloroquine, may make tumor cells more sensitive to radiation therapy
What is the current status of trial NCT01417403?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-08. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01417403?
The interventions under investigation include: radiation therapy (RADIATION), hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01417403?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.